Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkae416 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Mario Tumbarello und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnologies, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: Ceftazidime, Hematologic Neoplasms, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases, Tuscany Health Ecosystem.
Abstract (Originalsprache)
Objectives
To evaluate clinical impact of ceftazidime/avibactam on treating infections due to MDR Gram-negative bacteria in patients with haematological malignancies (HMs).
Methods
We conducted a retrospective, observational study at 17 Italian haematological wards that included patients with HMs receiving ceftazidime/avibactam for the treatment of suspected or proven infections. The primary endpoint was all-cause mortality 30 days after infection onset. Secondary endpoints included the development of in vitro ceftazidime/avibactam resistance, adverse reactions and infection relapse.
Results
Of 198 patients enrolled, 66 had fever of unknown origin and 132 had microbiologically proven infections (MPIs). Enterobacterales were responsible for 98 MPIs, with KPC producers accounting for 75% of these, and carbapenem-resistant Pseudomonas aeruginosa caused 25% of MPIs. The overall 30-day mortality rate was 17.7%. Infection relapse occurred in four patients with MPI. Patients who died within 30 days of infection onset tended to have pre-existing cerebrovascular diseases, a Charlson Comorbidity Index > 4 and septic shock at infection onset and had received inadequate initial antibiotic therapy. Thirty-day mortality was independently associated with septic shock at infection onset and inappropriate initial antibiotic therapy.
Conclusions
Our study provides further evidence about the effectiveness of ceftazidime/avibactam in treating infections in patients with HMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnologies, University of Siena, Siena, Italy.
- Infectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria Senese, Siena, Italy.
- Dipartimento Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Roma, Italy.
- Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma Tor Vergata, Roma, Italy.
- Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- SC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
ORCID-Profile: Mario Tumbarello
Förderung
- NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
- Tuscany Health Ecosystem
Zitieren
APA
Tumbarello, M., Giuliano, G., Criscuolo, M., Del Principe, M. I., Papayannidis, C., Fracchiolla, N. S., Dargenio, M., Cefalo, M., Nadali, G., Candoni, A., Buquicchio, C., Marchesi, F., Picardi, M., Lessi, F., Piedimonte, M., Prezioso, L., Piccini, M., Cattaneo, C., Busca, A., …, & Pagano, L. (2025). Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae416
Vancouver
Tumbarello M, Giuliano G, Criscuolo M, Del Principe MI, Papayannidis C, Fracchiolla NS, et al. Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae416
BibTeX
@article{Tumbarello2025,
author = {Tumbarello, Mario and Giuliano, Gabriele and Criscuolo, Marianna and Del Principe, Maria Ilaria and Papayannidis, Cristina and Fracchiolla, Nicola Stefano and Dargenio, Michela and Cefalo, Mariagiovanna and Nadali, Gianpaolo and Candoni, Anna and Buquicchio, Caterina and Marchesi, Francesco and Picardi, Marco and Lessi, Federica and Piedimonte, Monica and Prezioso, Lucia and Piccini, Matteo and Cattaneo, Chiara and Busca, Alessandro and Brunetti, Sara and Buzzatti, Elisa and Dedola, Alessandra and Sciumé, Mariarita and Di Renzo, Nicola and Cesini, Laura and Vatteroni, Alessandra and Raffaelli, Francesca and Pagano, Livio},
title = {Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkae416}
}
EUVIMED